NeuBase Therapeutics (NASDAQ: NBSE) Stake Acquisition: Symetryx Urges Board to Consider $1 per Share Dividend
NeuBase Therapeutics (NASDAQ: NBSE) saw significant interest and gained a whopping 106% after the company announced a 20% acquisition of their shares by Symetryx Corporation. To add to the excitement, Symetryx is now urging Neubase's Board of Directors to consider issuing a special dividend of $1 per share to the company's shareholders. Symetryx has acquired